MedImmune's Mott starts new career in VC
MedImmune's ex-CEO, David Mott, is starting a new career as a venture capitalist. He's been named a general partner at New Enterprise Associates, a busy investor in the biotech field. Mott says he will focus on biotechnology and specialty pharma.
Mott left MedImmune last July, a year after it was bought out by AstraZeneca for $15.6 billion. And the acquisition didn't leave Mott hurting for money. He got $133.5 million in stock option payouts and $12.2 million in other money.
"His broad sector expertise and strong ties within the biopharma community add substantial depth to NEA's healthcare practice," Peter J. Barris, a managing general partner, said in a statement.
- see NEA's release
- read the story from the Washington Post
Related Articles:
MedImmune's Mott heads for the exit
MedImmune CEO talks about AZ buyout
AstraZeneca snares MedImmune in $15.6B buyout
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
